Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

Clinical trial NCT06430905 · TERMINATED

Trial details

NCT number: NCT06430905
Sponsor: Hookipa Biotech GmbH
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Human Immunodeficiency Virus (HIV) Infection

Start date: 2024-07-01
Primary completion: 2025-07-18
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.